Literature DB >> 1436337

Causes of late renal allograft failure in the ciclosporin era.

J H Hong1, N Sumrani, V Delaney, R Davis, A Dibenedetto, K M Butt.   

Abstract

A single center experience of 514 ciclosporin-treated renal allografts which survived longer than 1 year was reviewed in order to analyze the causes of renal allograft loss beyond the 1st year post-transplantation and the contribution of selected parameters to long-term survival. 83 grafts were lost between 1 and 5 years with the most common causes of graft loss being chronic rejection (54%), death (14%), noncompliance (13%) and sepsis (11%). Actuarial 5-year graft survival rates, decaying from 100% at 1 year, of living related and cadaveric grafts were 88.6 and 79.5%, respectively. Parameters with a substantial influence on long-term survival included the quality of early graft function and incidence of acute rejection in the 1st year post-transplantation. A marker for long-term survival (> 5 years) was a significantly lower serum creatinine (177 mumol/l; < or = 2 mg/dl) at 1 year. We conclude that chronic rejection is responsible for the majority of late graft losses in the ciclosporin era as in the earlier azathioprine period.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1436337     DOI: 10.1159/000187058

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  6 in total

Review 1.  Modeling and simulation of adherence: approaches and applications in therapeutics.

Authors:  Leslie A Kenna; Line Labbé; Jeffrey S Barrett; Marc Pfister
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

Review 2.  Cyclosporin: a pharmacoeconomic evaluation of its use in renal transplantation.

Authors:  J E Frampton; D Faulds
Journal:  Pharmacoeconomics       Date:  1993-11       Impact factor: 4.981

3.  Causes of long-term graft failure in renal transplantation.

Authors:  K Tanabe; K Takahashi; H Toma
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

4.  Economic implications of the use of basiliximab in addition to triple immunosuppressive therapy in renal allograft recipients: a UK perspective.

Authors:  Stephen J Walters; Malcolm Whitfield; Ronald L Akehurst; James B Chilcott
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

5.  Long term outcome of renal transplantation in the pre cyclosporin era: one centre's experience.

Authors:  P J Conlon; W Medwar; S Hanson; J Donohoe; M Carmody; J J Walshe
Journal:  Ir J Med Sci       Date:  1995 Apr-Jun       Impact factor: 1.568

6.  MAGIC Study: Aims, Design and Methods using SystemCHANGE™ to Improve Immunosuppressive Medication Adherence in Adult Kidney Transplant Recipients.

Authors:  Cynthia L Russell; Shirley Moore; Donna Hathaway; An-Lin Cheng; Guoqing Chen; Kathy Goggin
Journal:  BMC Nephrol       Date:  2016-07-16       Impact factor: 2.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.